Many studies have shown that high serum concentrations of LDL-C are a major risk factor for coronary heart disease (CHD) and that lowering LDL-C levels will reduce the risk of major coronary events. Despite the availability of the National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines for the management of hyperlipidemia, most patients do not achieve their target LDL goals. OBJECTIVES: To evaluate the impact of clinical pharmacist intervention on LDL-C outcomes, in patients at high risk of cardiovascular events. METHODS: Forty-six patients with clinical atherosclerosis, a disease that confers high risk for CHD events, under the age of 70 with LDL >110mg/dL were identified from the data systems of Maccabi Healthcare Services (study group). The clinical pharmacist intervention consisted of meeting the physicians in order to present and discuss information regarding the ATP III recommendations on the management of hyperlipidaemia, and to go over patients clinical charts. Meetings were followed by written recommendations regarding LDL management and by periodic telephone follow-up to ensure implementation of the recommendations. Outcome analysis was based on a comparison between the study group and a control group (169 patients with similar characteristics). RESULTS: After 6-months follow-up 81% of the patients in the study group showed an improvement in LDL levels, with 24% achieving the ATP III goal for high risk patients of LDL<100mg/dL. In the control group the numbers were 61% and 16% respectively. CONCLUSION: Results of several studies evaluating intervention programs indicate that pharmacists can play a key role in improving cholesterol management in lipid clinics, community pharmacies, or hospitals. This study demonstrates for the first time in Israel that clinical pharmacist can have a positive impact on meeting LDL-C goals and better treatment outcomes.